You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Claims for Patent: 4,252,721

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 4,252,721

Title:	Cycloalkyltriazoles and process for obtaining same
Abstract:	Compounds of the general formula: ##STR1## in which alk and alk' represent the bivalent radicals; aliphatic alkyl chains; and R and R' represent the alkyl, halogen, hydrogen, alkyloxy, --OH, --CF.sub.3 or --SCH.sub.3 radicals. Said compounds of the formula I are effective and useful as antiglaucomic and antipsychotic agents and also as additive agents in the withdrawal treatment of various addictive conditions. Methods for their preparation are also disclosed.
Inventor(s):	Silvestrini; Bruno (Rome, IT), Baiocchi; Leandro (Rome, IT)
Assignee:	Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. (Rome, IT)
Application Number:	06/025,273
Patent Claims:	1. A compound of the formula: ##STR5## wherein "alk" is selected from the group consisting of linear and branched divalent alkene chains having from 1 to 10 carbon atoms; "alk'" is selected from the group consisting of linear and branched divalent alkene chains having from 1 to 5 carbon atoms; and each R and R' is selected from the group consisting of hydrogen, alkyl having from 1 to 5 carbon atoms, halogen, alkyloxy having from 1 to 3 carbon atoms, hydroxy, trifluoromethyl and methylthio. 2. A compound according to claim 1, consisting of the pharmaceutically acceptable non-toxic acid addition salt of formula I. 3. The compound according to claim 1, consisting of 3-[3-[4-(2-tolyl)-1-piperazinyl]propyl]-5,6,7,8-tetrahydro-s-triazol[4,3a] pyridine. 4. The compound according to claim 1, consisting of 3-[2-[4-(2-tolyl)-1-piperazinyl]ethyl]-6,7,8,9-tetrahydro-5H-s-triazol[4,3 a]azepine. 5. The compound according to claim 1, consisting of 3-[2-[4-(2-tolyl)-1-piperazinyl]-ethyl]-5,6,7,8-tetrahydro-s-triazol-[4,3- a]pyridine. 6. The compound according to claim 1, consisting of 3-[2-[4-(3-chloro-phenyl)-1-piperazinyl]-ethyl]-5,6,7,8-tetrahydro-s-triaz ol-[4,3-a]pyridine. 7. The compound according to claim 1, consisting of 3-[2-[4-(2-tolyl)-1-piperazinyl]-propyl/-6,7,8,9-tetrahydro-5H-s-triazol-[ 4,3-a]azepine. 8. The compound according to claim 1, consisting of 3-[2-[4-(2,5-di-chlorophenyl)-1-piperazinyl]-ethyl]-6,7,8,9-tetrahydro-5h- s-triazol[4,3-a]azepine. 9. The compound according to claim 1, consisting of 3-[2-[4-(2-methoxyphenyl-1-piperazinyl]-ethyl]-6,7,8,9-tetrahydro-5H-s-tri azol[4,3-a]-azepine.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.